Gorbonova 2000.

Study characteristics
Methods	Phase II parallel‐group RCT. Open label study.
Participants	Untreated metastatic melanoma. Randomised participants: 30.
Interventions	Two‐arm study: Cisplatin 100 mg/m² IV on day 3, aranoza 600 mg/m² IV on days 1 to 2 every 4 weeks (N = 14); Cisplatin 100 mg/m² IV on day 3, aranoza 600 mg/m² IV on days 1 to 2, and IFN‐α 3 mIU on days 5, 7, 9, 11, 13, 15, 17, 19 every 4 weeks (N = 14).
Outcomes	Tumour response
Notes	Cross‐over: not allowed. Quality of life: not reported. Participants with brain metastasis: excluded.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	There was insufficient information to permit judgement.
Allocation concealment (selection bias)	Unclear risk	There was insufficient information to permit judgement.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	As an open label study, no blinding of participants or personnel was possible. However, we believe that in this setting (metastatic melanoma), with the treatments tested and outcomes assessed, the knowledge of which intervention was received or administered (rather than the intervention itself), could not affect the outcomes under investigation. Therefore, we judged the risk of performance bias as low.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	There was insufficient information to permit judgement.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	There was insufficient information to permit judgement.
Selective reporting (reporting bias)	Unclear risk	There was insufficient information to permit judgement.
Other bias	Unclear risk	There was insufficient information to permit judgement.